Wedbush Issues Pessimistic Forecast for Geron Earnings

Geron Co. (NASDAQ:GERN) – Analysts at Wedbush cut their FY2026 earnings per share (EPS) estimates for shares of Geron in a research note issued on Wednesday, February 26th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will post earnings per share of $0.07 for the year, down from their previous forecast of $0.11. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Several other equities research analysts also recently weighed in on GERN. Barclays reiterated an “overweight” rating and issued a $4.00 price target (down from $9.00) on shares of Geron in a report on Thursday. Needham & Company LLC dropped their target price on Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday. Scotiabank decreased their price target on Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a research note on Thursday. B. Riley lowered Geron from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $3.50 to $2.00 in a research note on Thursday. Finally, Stifel Nicolaus decreased their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Stock Performance

Shares of NASDAQ:GERN opened at $1.74 on Friday. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. Geron has a 12 month low of $1.46 and a 12 month high of $5.34. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -5.44 and a beta of 0.53. The firm’s 50-day moving average is $2.97 and its 200 day moving average is $3.80.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million.

Hedge Funds Weigh In On Geron

Several institutional investors and hedge funds have recently modified their holdings of the stock. Alternative Investment Advisors LLC. raised its position in Geron by 13.3% during the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 2,612 shares in the last quarter. Rovin Capital UT ADV grew its stake in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 3,660 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Geron by 23.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,094 shares in the last quarter. Xponance Inc. lifted its stake in shares of Geron by 12.9% in the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 4,829 shares during the period. Finally, US Bancorp DE grew its position in Geron by 68.4% during the third quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 7,429 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.